China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with AstraZeneca (AZ, NASDAQ: AZN), securing exclusive retail distribution rights for the renowned digestive drug Losec (omeprazole) in mainland China. The financial details of this agreement have not been disclosed.
This partnership follows Baheal’s previous acquisition of commercial operation rights for AstraZeneca’s Onglyza (saxagliptin), further solidifying its presence in the pharmaceutical market.
Losec, recognized as the world’s first proton pump inhibitor (PPI) utilizing multiple unit pellet system (MUPS) technology, was initially launched in China in 1989. Today, the drug faces competition from a dozen generic versions available in the market, highlighting its enduring significance in digestive health.-Fineline Info & Tech
